Deep Brain Stimulation Post Failed Vagal Nerve Stimulation

Epilepsy, Drug Resistant Clinical Trial

— DBSpostVNS  

Official title:

Deep Brain Stimulation After Failed Vagal Nerve Stimulation for the Treatment of Drug-Resistant Epilepsy in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04181229
• Other study ID #: REB1000063803
• Status: Completed
• Phase: N/A
• Start date: November 25, 2019
• Est. completion date: August 30, 2023

Study information

• Verified date: March 2024
• Source: The Hospital for Sick Children
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, non-blinded, patient preference comparative trial for efficacy of deep brain stimulation (DBS) on drug-resistant epilepsy compared to continued vagal nerve stimulation (VNS) optimization in children with failed VNS. The two conditions being compared are therefore DBS (treatment) versus VNS (control). Fifty (50) patients will be recruited and enrolled in this pilot study (25 from The Hospital for Sick Children and 50 from CHU Sainte-Justine).

Description:

For children with epilepsy that have failed pharmacological and alternative treatments (drug-resistant epilepsy; [DRE]), surgical interventions may be considered. This includes vagus nerve stimulation (VNS) and deep brain stimulation (DBS). VNS for the treatment of DRE in children is an established and widely used treatment. Unfortunately, the positive response to VNS rate (>50% reduction in seizures) is not consistent, ranging from 26-55% in pediatric epilepsy patients. In children with failed VNS, defined as no improvement in seizure control after at least 1 year of treatment, they may undergo DBS as a recommended therapy. DBS is a safe and established treatment for various childhood neurological conditions and the indications for DBS in children continue to expand. It is currently unknown which children may benefit from DBS after failed VNS.

As a patient-preference randomized trial, patients and their parents will be introduced to the options of continuing with current VNS management (control arm) or trialing DBS (treatment arm). Patients and their parents will fall into three possible groups according to preference and willingness for randomization.

i) Patients with no strong preferences and consent to randomization ii) Patients with a preference, yet still consent to randomization iii) Patients who refuse randomization and opt for enrollment in a specific arm

Patients in the treatment arm will receive DBS of the centromedian nucleus. The centromedian nucleus is believed to reduce electrocortical activity in generalized epilepsy. The investigators hypothesize that stimulating this target will lead to a decrease in seizure severity and frequency in patients who have failed VNS; in comparison with patients who will have continued VNS treatment and optimization. Patients in the control arm will continue to be observed for 12 months with no change to their treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: August 30, 2023
• Est. primary completion date: March 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 18 Years

Eligibility

Inclusion Criteria:

1. Female or Male patients 8 years of age and over but not including 18 year olds.

2. Diagnosis of drug-resistant epilepsy with failure after trial of two anti-epileptic medications (as defined by Kwan et al. 20093). All children screened for entry into the study will be re-diagnosed by a neurologist prior to entry.

3. Failure of vagal nerve stimulation, defined as the same or increased frequency and severity of seizures at 12 months or more after instigation and optimization of therapy. Failure is defined objectively and subjectively. Objective evidence includes caregiver logs, clinician assessment, or neuromonitoring if the clinician has documented a baseline status prior to instigation of vagal nerve stimulation. Subjective measures include family or patient opinion that seizure frequency or severity has not improved.

4. Parents or legal guardians, including caregivers, who are informed and able to give written consent.

5. Ability to comply with all testing, follow-ups and study appointments and protocols for 12 months following the end of the duration of the study.

Exclusion Criteria:

1. Substance dependence or abuse in the last 6 months, excluding caffeine and nicotine

2. Any contraindication to MRI scanning. A preoperative MRI scan is essential to planning DBS and therefore any contraindication to MRI is a contraindication to enrollment in the study.

3. Unwillingness or inability to return to SickKids for follow-up visits.

Related Conditions & MeSH terms

• Drug Resistant Epilepsy
• Epilepsy
• Epilepsy, Drug Resistant

Intervention

Procedure:
• Deep brain stimulation
Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.

Locations

Country	Name	City	State
Canada	The Hospital for Sick Children	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
The Hospital for Sick Children	St. Justine's Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seizure reduction after DBS surgery	Measured by the Class on the Engel Epilepsy Surgery Outcome Scale, where: Class I: Free of disabling seizures IA: Completely seizure-free since surgery IB: Non disabling simple partial seizures only since surgery IC: Some disabling seizures after surgery, but free of disabline seizures for at least 2 years ID: Generalized convulsions with antiepileptic drug withdrawal only Class II: Rare disabling seizures ("almost seizure-free") IIA: Initially free of disabling seizures but has rare seizures now IIB: Rare disabling seizures since surgery IIC: More than rare disabling seiuzres after surgery, but rare seizures for at least 2 years IID: Nocturnal seizures only Class III: Worthwhile improvement IIIA: Worthwhile seiuzre reduction IIIB: Prolonged seiuzre-free intervals amounting to greater than half the follow-up period, but not less than 2 years Class IV: No worthwhile improvement IVA: Significant seizure reduction IVB: No appreciable change IVC: Seizures worse	Assessed post surgery up to 1 year
Primary	Seizure reduction after VNS surgery	Measured by the Class on the McHugh Scale, where: Class I (80-100% reduction in seizure frequency) Class II (50-79% reduction in seizure frequency) Class III (< 50% reduction in seizure frequency) Class IV (Magnet benefit only) Class V (No improvement)	Assessed post surgery up to 1 year
Secondary	Change in patient-perceived seizure severity	Measured by the Liverpool Seizure Severity Scale (LSSS) which measures patients' own perceptions of changes in seizure severity. The LSSS is rated on a 4-point likert scale, where 1 represents "always" (worse outcome) and 4 represents "never" (better outcome).	Assessed pre surgery and post surgery up to 1 year
Secondary	Change in parent-perceived seizure severity	Measured by the Hague Seizure Severity (HASS) scale which measures parents' perceptions of changes in seizure severity. The HASS is measured on a 4 point likert-scale, where 1 represents "always" (worse outcome) and 4 represents "never" (better outcome).	Assessed pre surgery and post surgery up to 1 year
Secondary	Change in self-reported quality of life	Measured by the Quality of Life in Epilepsy for Adolescents scale (QOLIE-AD-48), a two-part scale. Part 1 measures general health on a 5 point scale where 1 represents "excellent" (better outcome) and 5 represents "poor" (worse outcome). Part 2 measures effects of epilepsy and antiepilepsy medications on a 5 point scale where 1 represents "very often" (worse outcome) and 5 represents "never" (better outcome).	Assessed pre surgery and post surgery up to 1 year